Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluBuBe Conditioning in Haploidentical HSCT
NCT04942730Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoblastic lymphoma (LL) and 2 more, sponsored by First Saint Petersburg State Medical University. Primary endpoint: Incidence of primary and secondary graft failure at 100 days. Started Jan 2021; status: completed.
02
Drugs
bendamustine
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)lymphoblastic lymphoma (LL)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04942730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942730.